To trade away aluminum and steel workers’ home market in exchange for padding Big Tech’s bottom line overseas is immoral and wrong. The Section 232 actions on aluminum and steel should be singularly focused on rebuilding domestic output across the supply chains, not used as leverage to help Google and Meta become even more profitable.
The America First Investment Policy rightly seeks to ensure that Wall Street can no longer channel hundreds of billions of U.S. dollars into companies that build China’s military, commit human rights atrocities, and threaten our national security. CPA strongly supports Chairman Moolenaar’s effort to codify this policy into law.
The Senate Special Committee on Aging was back at it this week discussing the woeful predicament of the domestic generic drug industry and its import-facing supply chain. This time, the Committee heard from four generic drug makers opposed to advocacy groups and Washington think tanks.
The Netherlands is the latest example of a country succumbing to China’s leadership position in critical supply chains.
Witnesses at a Senate hearing on Wednesday, Oct. 29 titled “The Future of Biotech” discussed ways to facilitate reshoring and making it attractive to expand in the U.S. and conduct R&D here instead of in China.
President Trump has already made the most important deal of his life—his promise to the American people to end U.S. dependence on China and rebuild our domestic industrial capacity.
There are very few things that Democrats and Republicans agree on. One of them is the need to support domestic shipbuilding beyond just military vessels.
The report, titled “America’s Chip-for-Chip Tariff Policy: The Urgent Fight to Reclaim Industrial Independence Before It’s Too Late,” finds that the United States now produces only 10 percent of the world’s chips—and almost none of the most advanced ones—while China has captured the majority of global capacity for legacy chips, the mature semiconductors essential to cars, medical devices, and industrial equipment.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
The Trump administration’s section 232 investigation into medical devices and personal protective equipment is a vital step toward ensuring America takes back control over its production and domestic supply of critical medical products.
